WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/030466    International Application No.:    PCT/JP2017/028928
Publication Date: 15.02.2018 International Filing Date: 09.08.2017
C07D 213/42 (2006.01), A61K 31/437 (2006.01), A61K 31/4375 (2006.01), A61K 31/44 (2006.01), A61K 31/4406 (2006.01), A61K 31/444 (2006.01), A61K 31/4965 (2006.01), A61K 31/497 (2006.01), A61K 31/505 (2006.01), A61K 31/506 (2006.01), A61K 31/53 (2006.01), A61K 31/5383 (2006.01), A61P 35/00 (2006.01), A61P 43/00 (2006.01), C07D 213/65 (2006.01), C07D 213/68 (2006.01), C07D 213/73 (2006.01), C07D 213/75 (2006.01), C07D 239/20 (2006.01), C07D 239/42 (2006.01), C07D 241/12 (2006.01), C07D 241/20 (2006.01), C07D 253/06 (2006.01), C07D 401/12 (2006.01), C07D 401/14 (2006.01), C07D 403/12 (2006.01), C07D 405/12 (2006.01), C07D 471/04 (2006.01), C07D 498/04 (2006.01)
Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410045 (JP)
Inventors: FUJIMOTO, Jun; (JP).
LIU, Xin; (CN).
KURASAWA, Osamu; (JP).
TAKAGI, Terufumi; (JP).
CARY, Douglas Robert; (JP).
BANNO, Hiroshi; (JP).
ASANO, Yasutomi; (JP).
KOJIMA, Takuto; (JP)
Agent: TAKASHIMA, Hajime; (JP)
Priority Data:
2016-158038 10.08.2016 JP
2017-016275 31.01.2017 JP
(JA) 複素環化合物
Abstract: front page image
(EN)The purpose of the present invention is to provide a heterocyclic compound that can have GCN2-inhibiting activity and is expected to be useful in the prevention and treatment of GCN 2-related diseases and the like, including cancer. Provided is a compound, or a salt thereof, represented by formula (I) (in the formula, each symbol is as defined in the specification).
(FR)Le but de la présente invention est de fournir un composé hétérocyclique qui peut avoir une activité inhibitrice de GCN2 et est supposé être utile dans la prévention et le traitement de maladies liées au GCN 2 et similaires, y compris le cancer. L'invention concerne un composé, ou un sel de celui-ci, représenté par la formule (I) (dans la formule, chaque symbole est tel que défini dans la description).
(JA)GCN2阻害作用を有し得、がんを含むGCN2関連疾患等の予防・治療に有用であることが期待される複素環化合物を提供すること。式(I):〔式中、各記号は、明細書に記載の通りである。〕 で表される化合物またはその塩。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)